CT-guided radiofrequency ablation for the treatment of early stage non-small-cell lung cancer:clinical analysis of 60 cases
10.3969/j.issn.1008-794X.2015.05.013
- VernacularTitle:早期非小细胞肺癌CT引导射频消融治疗60例临床分析
- Author:
Jingqi HAN
;
Chuanyu ZHANG
;
Yong LI
;
Changgong CHI
;
Deli PAN
- Publication Type:Journal Article
- Keywords:
radiofrequency ablation;
non-small-cell lung cancer;
CT-guidance
- From:
Journal of Interventional Radiology
2015;(5):414-417
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety, efficacy and local control effect of CT- guided radiofrequency ablation (RFA) in treating non-small-cell lung cancer (NSCLC) that is inoperable or the surgical treatment is refused by the patient. Methods Between March 2007 and March 2010 at authors’ hospital, a total of 68 procedures of CT-guided RFA were carried out in 60 patients with early stage NSCLC. The patients included 37 males and 23 females with a mean age of 68.5 years. Pathologically, the lesions included squamous cell carcinoma (n=23, 38.3%), adenocarcinoma (n=31, 51.7%), large cell carcinoma (n=2, 3.3%) and adeno-squamous carcinoma (n=4, 6.7%). The mean diameter of the lesions was 3.8 cm (1.8-6.8 cm). The overall survival rate, cancer-specific survival rate and local progression-free survival rate were evaluated. Results RFA procedure was well tolerated by all patients with an average ablation time of 35 min (18-63 min). The main intraprocedural complication was pneumothorax (n=17, 28.3%). No death occurred during perioperative period. The median local progression-free survival time was 28 months, the median survival time was 32 months, and the one-, 2- and 3-year local progression-free survival rate were 94.6%, 83.1%and 73.6%, respectively. Conclusion For patients with inoperable NSCLC and patients with NSCLC who refuse to receive surgery, CT-guided RFA is a safe and effective treatment. This therapy can significantly improve the local progression-free survival rate.
